Sclederma of Poria cocos exerts its diuretic effect via suppression of renal aquaporin-2 expression in rats with chronic heart failure

Journal of Ethnopharmacology

Volumn 155, Issue 1, 2014, Pages 563-571

  Wu, Zhen Li ^a   Ren, Hao ^a,b   Lai, Wen Yan ^a,b   Lin, Sheng ^a   Jiang, Rong Yan ^a   Ye, Tao Chun ^a   Shen, Qian Bo ^a   Zeng, Qing Chun ^a,b   Xu, Ding Li ^a,b  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

Aquaporin 2; Arginine vasopressin; Chronic heart failure; Hoelen; Sclederma of Poria cocos; Vasopressin type 2 receptor

Indexed keywords

AQUAPORIN 2; ARGIPRESSIN; BRAIN NATRIURETIC PEPTIDE; DIURETIC AGENT; FUROSEMIDE; MESSENGER RNA; PORIA COCOS EXTRACT; PORIA COCOS SCLEDERMA EXTRACT; UNCLASSIFIED DRUG; VASOPRESSIN V2 RECEPTOR; PLANT EXTRACT; VASOPRESSIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIURESIS; DOWN REGULATION; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG SCREENING; ELECTROLYTE DISTURBANCE; EXPERIMENTAL HEART FAILURE; GENE EXPRESSION; KIDNEY MEDULLA; LOW DRUG DOSE; MALE; NONHUMAN; PLANT STRUCTURES; PORIA COCOS; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; RAT; SCLEDERMA; SPRAGUE DAWLEY RAT; URINARY EXCRETION; URINE OSMOLALITY; URINE VOLUME; ANIMAL; BLOOD; CHEMISTRY; CHRONIC DISEASE; COMPARATIVE STUDY; COMPLICATION; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HEART FAILURE; HEART INFARCTION; ISOLATION AND PURIFICATION; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PORIA; TIME;

ADMINISTRATION, ORAL; ANIMALS; AQUAPORIN 2; ARGININE VASOPRESSIN; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; DIURETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; FUROSEMIDE; GENE EXPRESSION REGULATION; HEART FAILURE; MALE; MYOCARDIAL INFARCTION; PLANT EXTRACTS; PORIA; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, VASOPRESSIN; TIME FACTORS;

EID: 84904958835     PISSN: 03788741     EISSN: 18727573     Source Type: Journal    
DOI: 10.1016/j.jep.2014.05.054     Document Type: Article

References (37)

1. H. Amlal, S. Sheriff, and M. Soleimani Upregulation of collecting duct aquaporin-2 by metabolic acidosis: role of vasopressin American Journal of Physiology Cell Physiology 286 2004 C1019 C1030
2. R. Bouley, H.A. Lu, P. Nunes, N. Da Silva, M. McLaughlin, Y. Chen, and D. Brown Calcitonin has a vasopressin-like effect on aquaporin-2 trafficking and urinary concentration Journal of the American Society of Nephrology 22 2011 59 72
3. D.C. Brater Diuretic therapy The New England Journal of Medicine 339 1998 387 395
4. K. Eto, Y. Noda, S. Horikawa, S. Uchida, and S. Sasaki Phosphorylation of aquaporin-2 regulates its water permeability Journal of Biological Chemistry 285 2010 40777 40784
5. Y.L. Feng, P. Lei, T. Tian, L. Yin, D.Q. Chen, H. Chen, Q. Mei, Y.Y. Zhao, and R.C. Lin Diuretic activity of some fractions of the epidermis of Poria cocos Journal of Ethnopharmacology 150 2013 1114 1118
6. R.A. Fenton, C.N. Pedersen, and H.B. Moeller New insights into regulated aquaporin-2 function Current Opinion in Nephrology and Hypertension 22 2013 551 558
7. H. Funayama, T. Nakamura, T. Saito, A. Yoshimura, M. Saito, M. Kawakami, and S.E. Ishikawa Urinary excretion of aquaporin-2 water channel exaggerated dependent upon vasopressin in congestive heart failure Kidney International 66 2004 1387 1392
8. N. Gassanov, N. Semmo, M. Semmo, A.M. Nia, U. Fuhr, and F. Er Arginine vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion (SIADH) European Journal of Clinical Pharmacology 67 2011 333 346
9. M. Gheorghiade, M.A. Konstam, J.C. Burnett Jr., L. Grinfeld, A.P. Maggioni, K. Swedberg, J.E. Udelson, F. Zannad, T. Cook, J. Ouyang, C. Zimmer, and C. Orlandi Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST clinical statustTrials JAMA 297 2007 1332 1343
10. A.S. Go, D. Mozaffarian, V.L. Roger, E.J. Benjamin, J.D. Berry, W.B. Borden, D.M. Bravata, S. Dai, E.S. Ford, C.S. Fox, S. Franco, H.J. Fullerton, C. Gillespie, S.M. Hailpern, J.A. Heit, V.J. Howard, M.D. Huffman, B.M. Kissela, S.J. Kittner, D.T. Lackland, J.H. Lichtman, L.D. Lisabeth, D. Magid, G.M. Marcus, A. Marelli, D.B. Matchar, D.K. McGuire, E.R. Mohler, C.S. Moy, M.E. Mussolino, G. Nichol, N.P. Paynter, P.J. Schreiner, P.D. Sorlie, J. Stein, T.N. Turan, S.S. Virani, N.D. Wong, D. Woo, and M.B. Turner Executive summary: heart disease and stroke statistics-2013 update: a report from the American Heart Association Circulation 127 2013 143 152
11. S.R. Goldsmith, and M. Gheorghiade Vasopressin antagonism in heart failure Journal of the American College of Cardiology 46 2005 1785 1791
12. N. Hadrup, J.S. Petersen, J. Praetorius, E. Meier, M. Graebe, L. Brond, D. Staahltoft, S. Nielsen, S. Christensen, D.R. Kapusta, and T.E. Jonassen Opioid receptor-like 1 stimulation in the collecting duct induces aquaresis through vasopressin-independent aquaporin-2 downregulation The American Journal of Physiology. Renal Physiology 287 2004 F160 F168
13. M. Inoue, K. Okajima, K. Itoh, Y. Ando, N. Watanabe, T. Yasaka, S. Nagase, and Y. Morino Mechanism of furosemide resistance in analbuminemic rats and hypoalbuminemic patients Kidney International 32 1987 198 203
14. P. Ivarsen, J. Frokiaer, N.K. Aagaard, E.F. Hansen, F. Bendtsen, S. Nielsen, and H. Vilstrup Increased urinary excretion of aquaporin 2 in patients with liver cirrhosis Gut 52 2003 1194 1199
15. D. Kelly, I.B. Squire, S.Q. Khan, P. Quinn, J. Struck, N.G. Morgenthaler, J.E. Davies, and L.L. Ng C-terminal provasopressin (copeptin) is associated with left ventricular dysfunction, remodeling, and clinical heart failure in survivors of myocardial infarction Journal of Cardiac Failure 14 2008 739 745
16. J.D. Klein, R.B. Gunn, B.R. Roberts, and J.M. Sands Down-regulation of urea transporters in the renal inner medulla of lithium-fed rats Kidney International 61 2002 995 1002
17. M.A. Konstam, M. Gheorghiade, J.C. Burnett Jr., L. Grinfeld, A.P. Maggioni, K. Swedberg, J.E. Udelson, F. Zannad, T. Cook, J. Ouyang, C. Zimmer, and C. Orlandi Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial JAMA 297 2007 1319 1331
18. T.J. Li, Y. Qiu, J.Q. Mao, P.Y. Yang, Y.C. Rui, and W.S. Chen Protective effects of Guizhi-Fuling-Capsules on rat brain ischemia/reperfusion injury Journal Of Pharmacological Sciences 105 2007 34 40
19. I.M. Liu, T.F. Tzeng, S.S. Liou, and C.J. Chang The amelioration of streptozotocin diabetes-induced renal damage by Wu-Ling-San (Hoelen Five Herb Formula), a traditional Chinese prescription Journal of Ethnopharmacology 124 2009 211 218
20. Y. Matsumura, S. Uchida, T. Rai, S. Sasaki, and F. Marumo Transcriptional regulation of aquaporin-2 water channel gene by cAMP Journal of the American Society of Nephrology 8 1997 861 867
21. J.J. McMurray, S. Adamopoulos, S.D. Anker, A. Auricchio, M. Bohm, K. Dickstein, V. Falk, G. Filippatos, C. Fonseca, M.A. Gomez-Sanchez, T. Jaarsma, L. Kober, G.Y. Lip, A.P. Maggioni, A. Parkhomenko, B.M. Pieske, B.A. Popescu, P.K. Ronnevik, F.H. Rutten, J. Schwitter, P. Seferovic, J. Stepinska, P.T. Trindade, A.A. Voors, F. Zannad, and A. Zeiher ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC European Heart Journal 33 2012 1787 1847
22. M. Metra, S. Bugatti, L. Bettari, V. Carubelli, R. Danesi, V. Lazzarini, C. Lombardi, and L.D. Cas Can we improve the treatment of congestion in heart failure? Expert Opinion on Pharmacotherapy 12 2011 1369 1379
23. G. Michael Felker Diuretic management in heart failure Congestive Heart Failure 16 Suppl 1 2010 S68 S72
24. T. Mondritzki, P. Kolkhof, H.N. Sabbah, M. Gheorghiade, C. Furstner, C. Schmeck, H. Siedentop, S. Schaefer, and H. Truebel Differentiation of arginine vasopressin antagonistic effects by selective V2 versus dual V2/V1a receptor blockade in a preclinical heart failure model American Journal of Therapeutics 18 2011 31 37
25. H. Morooka, Y. Iwanaga, Y. Tamaki, T. Takase, Y. Akahoshi, Y. Nakano, H. Fujiki, and S. Miyazaki Chronic administration of oral vasopressin type 2 receptor antagonist tolvaptan exerts both myocardial and renal protective effects in rats with hypertensive heart failure Circulation Heart Failure 5 2012 484 492
26. M.J. Radin, M.J. Yu, L. Stoedkilde, R.L. Miller, J.D. Hoffert, J. Frokiaer, T. Pisitkun, and M.A. Knepper Aquaporin-2 regulation in health and disease Veterinary Clinical Pathologyl 41 2012 455 470
27. U. Schafer, T. Kurz, D. Jain, F. Hartmann, A. Dendorfer, R. Tolg, W. Raasch, P. Dominiak, H. Katus, and G. Richardt Impaired coronary flow and left ventricular dysfunction after mechanical recanalization in acute myocardial infarction: role of neurohumoral activation? Basic Research in Cardiology 97 2002 399 408
28. R.W. Schrier Use of diuretics in heart failure and cirrhosis Seminars in Nephrology 31 2011 503 512
29. R.W. Schrier, and W.T. Abraham Hormones and hemodynamics in heart failure The New England Journal of Medicine 341 1999 577 585
30. D. Staahltoft, S. Nielsen, N.R. Janjua, S. Christensen, O. Skott, N. Marcussen, and T.E. Jonassen Losartan treatment normalizes renal sodium and water handling in rats with mild congestive heart failure The American Journal of Physiology. Renal Physiology 282 2002 F307 F315
31. J. Starklint, J.N. Bech, O. Nyvad, P. Jensen, and E.B. Pedersen Increased urinary aquaporin-2 excretion in response to furosemide in patients with chronic heart failure Scandinavian Journal of Clinical and Laboratory Investigation 66 2006 55 66
32. J. Starklint, J.N. Bech, and E.B. Pedersen Urinary excretion of aquaporin-2 after furosemide and felodipine in healthy humans Scandinavian Journal of Clinical and Laboratory Investigation 65 2005 249 261
33. P.T. Veeraveedu, K. Watanabe, M. Ma, S.S. Palaniyandi, K. Yamaguchi, K. Suzuki, M. Kodama, and Y. Aizawa Effects of nonpeptide vasopressin V2 antagonist tolvaptan in rats with heart failure Biochemical Pharmacology 74 2007 1466 1475
34. J.L. Wilson, C.A. Miranda, and M.A. Knepper Vasopressin and the regulation of aquaporin-2 Clinical and Experimental Nephrology 17 2013 751 764
35. D. Xu, X. Yin, H. Hui, Y. Deng, and H. Ren Urinary excretion of aquaporin-2 water channel protein in chronic heart failure rats Chinese Medical Journal (English) 114 2001 899 901
36. D.L. Xu, P.Y. Martin, M. Ohara St, J. John, T. Pattison, X. Meng, K. Morris, J.K. Kim, and R.W. Schrier Upregulation of aquaporin-2 water channel expression in chronic heart failure rat Journal of Clinical Investigation 99 1997 1500 1505
37. G. Zhang, X. Zeng, L. Han, J.A. Wei, and H. Huang Diuretic activity and kidney medulla AQP1, AQP2, AQP3, V2R expression of the aqueous extract of sclerotia of Polyporus umbellatus FRIES in normal rats Journal of Ethnopharmacology 128 2010 433 437